REV-403
Solid Cancers (EGFR x PDL1)
Key Facts
About Revitope Oncology
Revitope Oncology is pioneering a modular, precision immunotherapy platform to address the critical safety challenge of on-target, off-tumor toxicity in cancer treatment. Its proprietary Two GATE™ (Guided Antibody Tumor Engager) technology utilizes a dual-antigen 'AND' gate and tumor-specific protease activation to conditionally engage T cells only at the tumor site. The company has advanced its lead program, REV-403 (targeting EGFR and PDL1), into Phase 1 trials and has built a broader preclinical pipeline through internal efforts and strategic collaborations with partners like Junshi Biosciences and Genmab. Founded in 2013 and based in Cambridge, Massachusetts, Revitope is a private, pre-revenue biotech focused on expanding the therapeutic window for immuno-oncology drugs.
View full company profile